Supernus Pharmaceuticals’ (SUPN) Neutral Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research note released on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has a $36.00 price objective on the specialty pharmaceutical company’s stock.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $31.91 on Wednesday. The firm has a market cap of $1.76 billion, a P/E ratio of 29.82 and a beta of 0.90. The business’s 50 day moving average price is $37.27 and its 200-day moving average price is $35.37. Supernus Pharmaceuticals has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Insider Activity

In other news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 in the last quarter. 9.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SUPN. Raiffeisen Bank International AG bought a new stake in Supernus Pharmaceuticals in the 4th quarter worth about $25,000. GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $42,000. Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $52,000. Finally, Headlands Technologies LLC boosted its holdings in shares of Supernus Pharmaceuticals by 203.0% in the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,015 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.